Establishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic Nephropathy

NCT ID: NCT04976426

Last Updated: 2021-07-26

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2026-12-31

Brief Summary

Diabetic kidney disease(DKD) is a leading cause of chronic kidney disease and end-stage renal disease across the world. Early identification of DKD is vitally important for the effective prevention and control of it. However, the available indicators are doubtful in the early diagnosis of DKD. This study aims to develop a novel system of multidimensional network biomarkers (MDNBs) to estimating early diabetic nephropathy, and further validating the performance of the novel systemin in prediction of the risk for early diabetic nephropathy by a nested case-control study.

Detailed Description

Patients with a history of more than 5 years of diabetes without DKD were recruited. At the baseline visit, the patients' serum, plasma and urine were collected after obtaining informed patient consent. Simultaneously, the basic information, anthropometric indicators (including height, weight, waist circumference, hip circumference, blood pressure), past history, family history, menstrual history, birth history, medication history, lifestyle of the patients were registered, and the corresponding laboratory examination and auxiliary examination were carried out according to the diagnostic process. All data and data were entered into the database for later analysis. After 5years of follow up, subjects will be divided into two groups(the new onset DKD group and the non-DKD group), the base line level of MDNBs were tested in the two group to validate the performance of the novel MDNBs in in prediction of the risk for early diabetic nephropathy.

Conditions

Diabetes Mellitus; Biomarkers; Diabetic Kidney Disease; Early Diagnosis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Subjects who have signed informed consent.
• Subjects who were diagnosed with diabetes at least 5 years.
• Subjects showed good compliance, and the follow-up data was available for >5 years.

Exclusion Criteria

• Renal diseases caused by other causes, including primary and secondary;
• All kinds of acute infections;
• The expected life expectancy (life expectancy or related diseases) was less than 5 years according to the researcher's judgment.
• Drug users or drug abusers;
• Sexually transmitted diseases such as viral hepatitis, AIDS and syphilis, and infectious diseases such as tuberculosis are in an active period;
• Any situation judged by the researcher that affects enrollment.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Second Affiliated Hospital of Wenzhou Medical University

OTHER

Sponsor Role: collaborator

Lishui Country People's Hospital

OTHER

Sponsor Role: collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zheng Chao, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

the Second Affiliated Hospital Zhejiang University Schoolof Medicine

Central Contacts

Zheng Chao, MD, PhD

Role: CONTACT

wallbb_1022@163.com

8615057585907

Yikai Zhang, PhD

Role: CONTACT

smt198853@163.com

8613706673733

Other Identifiers

zhengchao3

Identifier Type: -

Identifier Source: org_study_id